Follow
Georgina Meneses-Lorente
Georgina Meneses-Lorente
Industry
Verified email at roche.com
Title
Cited by
Cited by
Year
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study
PA Cassier, A Italiano, CA Gomez-Roca, C Le Tourneau, M Toulmonde, ...
The Lancet Oncology 16 (8), 949-956, 2015
3762015
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like …
CA Gomez-Roca, A Italiano, C Le Tourneau, PA Cassier, M Toulmonde, ...
Annals of Oncology 30 (8), 1381-1392, 2019
1702019
Multiplex proteomic analysis by two‐dimensional differential in‐gel electrophoresis
MR Knowles, S Cervino, HA Skynner, SP Hunt, C de Felipe, K Salim, ...
PROTEOMICS: International Edition 3 (7), 1162-1171, 2003
1372003
Gene expression profiling of drug metabolism and toxicology markers using a low-density DNA microarray
F De Longueville, D Surry, G Meneses-Lorente, V Bertholet, V Talbot, ...
Biochemical pharmacology 64 (1), 137-149, 2002
1042002
Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion
AL Siebel, AK Natoli, FYT Yap, AL Carey, M Reddy-Luthmoodoo, ...
Circulation research 113 (2), 167-175, 2013
872013
Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors
GW Robinson, AJ Gajjar, KM Gauvain, EM Basu, ME Macy, LD Maese, ...
J Clin Oncol 37 (15_suppl), 10009, 2019
832019
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
AV Desai, GW Robinson, K Gauvain, EM Basu, ME Macy, L Maese, ...
Neuro-oncology 24 (10), 1776-1789, 2022
772022
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive …
A Schneeweiss, TW Park-Simon, J Albanell, U Lassen, J Cortés, V Dieras, ...
Investigational new drugs 36, 848-859, 2018
762018
89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors
F Bensch, LE Lamberts, MM Smeenk, A Jorritsma-Smit, ...
Clinical Cancer Research 23 (20), 6128-6137, 2017
762017
First-in-human phase I study of lumretuzumab, a glycoengineered humanized anti-HER3 monoclonal antibody, in patients with metastatic or advanced HER3-positive solid tumors
D Meulendijks, W Jacob, M Martinez-Garcia, A Taus, MP Lolkema, ...
Clinical Cancer Research 22 (4), 877-885, 2016
732016
A proteomic investigation of drug-induced steatosis in rat liver
G Meneses-Lorente, PC Guest, J Lawrence, N Muniappa, MR Knowles, ...
Chemical research in toxicology 17 (5), 605-612, 2004
732004
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade
C Gomez-Roca, P Cassier, D Zamarin, JP Machiels, JLP Gracia, FS Hodi, ...
Journal for immunotherapy of cancer 10 (5), 2022
632022
A quantitative high-throughput trapping assay as a measurement of potential for bioactivation
G Meneses-Lorente, MZ Sakatis, T Schulz-Utermoehl, C De Nardi, ...
Analytical biochemistry 351 (2), 266-272, 2006
622006
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients
JP Machiels, C Gomez-Roca, JM Michot, D Zamarin, T Mitchell, G Catala, ...
Journal for ImmunoTherapy of Cancer 8 (2), 2020
612020
Physiologically based absorption modelling to explore the impact of food and gastric pH changes on the pharmacokinetics of entrectinib
N Parrott, C Stillhart, M Lindenberg, B Wagner, K Kowalski, E Guerini, ...
The AAPS Journal 22, 1-13, 2020
492020
CYP isoform induction screening in 96-well plates: use of 7-benzyloxy-4-trifluoromethylcoumarin as a substrate for studies with rat hepatocytes
RJ Price, D Surry, AB Renwick, G Meneses-Lorente, BG Lake, DC Evans
Xenobiotica 30 (8), 781-795, 2000
452000
Phase I study of RG7155, a novel anti-CSF1R antibody, in patients with advanced/metastatic solid tumors.
CA Gomez-Roca, PA Cassier, A Italiano, M Cannarile, C Ries, A Brillouet, ...
Journal of Clinical Oncology 33 (15_suppl), 3005-3005, 2015
392015
Phase Ib study of lumretuzumab plus cetuximab or erlotinib in solid tumor patients and evaluation of HER3 and heregulin as potential biomarkers of clinical activity
D Meulendijks, W Jacob, EE Voest, M Mau-Sorensen, M Martinez-Garcia, ...
Clinical Cancer Research 23 (18), 5406-5415, 2017
382017
An evaluation of a low-density DNA microarray using cytochrome P450 inducers
G Meneses-Lorente, F de Longueville, S Dos Santos-Mendes, TP Bonnert, ...
Chemical research in toxicology 16 (9), 1070-1077, 2003
342003
Phase 1 study of RG7155, a novel anti-CSF1R antibody, in patients with locally advanced pigmented villonodular synovitis (PVNS).
PA Cassier, CA Gomez-Roca, A Italiano, M Cannarile, C Ries, A Brillouet, ...
Journal of Clinical Oncology 32 (15_suppl), 10504-10504, 2014
322014
The system can't perform the operation now. Try again later.
Articles 1–20